Cargando…

PD-L1 and HIF-2α Upregulation in Head and Neck Paragangliomas after Embolization

SIMPLE SUMMARY: In solid tumors, hypoxia activates pathways associated with tumor progression and induces alterations in the immune microenvironment such as the upregulation of programmed cell death-ligand 1 (PD-L1). Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors which a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer, Alessa, Maccio, Umberto, Wang, Katharina, Friemel, Juliane, Broglie Daeppen, Martina A., Vetter, Diana, Lehmann, Kuno, Reul, Astrid, Robledo, Mercedes, Hantel, Constanze, Bechmann, Nicole, Pacak, Karel, Zitzmann, Kathrin, Auernhammer, Christoph J., Grossman, Ashley B., Beuschlein, Felix, Nölting, Svenja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650267/ https://www.ncbi.nlm.nih.gov/pubmed/37958373 http://dx.doi.org/10.3390/cancers15215199

Ejemplares similares

Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses
por: Fischer, Alessa, et al.
Publicado: (2023)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Three Dimensional Models of Endocrine Organs and Target Tissues Regulated by the Endocrine System
por: Luca, Edlira, et al.
Publicado: (2023)

Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
por: Nölting, Svenja, et al.
Publicado: (2019)

The Vault Complex Is Significantly Involved in Therapeutic Responsiveness of Endocrine Tumors and Linked to Autophagy under Chemotherapeutic Conditions
por: Bornstein, Stefan, et al.
Publicado: (2023)

Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches
por: Gieldon, Laura, et al.
Publicado: (2019)

Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion
por: Li, Minghao, et al.
Publicado: (2021)

Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine
por: Richter, Susan, et al.
Publicado: (2022)

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
por: Zhang, Liang, et al.
Publicado: (2023)

THU612 SDHx Pheochromocytoma/Paraganglioma Has Elevation Of Arginine And Lysine Metabolites
por: Ghayee, Hans Kumar, et al.
Publicado: (2023)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

New insights on the pathogenesis of paraganglioma and pheochromocytoma
por: Kantorovich, Vitaly, et al.
Publicado: (2018)

Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF2α mutation: A case report
por: Abdullah, Ahmad Esmaeel, et al.
Publicado: (2017)

Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas–Effect of Different Statins on Mouse Pheochromocytoma Cells
por: Fliedner, Stephanie M. J., et al.
Publicado: (2014)

SUN-330 Non-Mosaic Somatic HIF2A Mutations Associated with Late-Onset Polycythemia-Paraganglioma Syndrome: Newly Recognized Subclass of Polycythemia-Paraganglioma Syndrome
por: Pang, Ying, et al.
Publicado: (2019)

Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging
por: Blanchet, Elise M., et al.
Publicado: (2012)

Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells
por: Bechmann, Nicole, et al.
Publicado: (2019)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
por: Ilanchezhian, Maran, et al.
Publicado: (2020)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors
por: Ghayee, Hans Kumar, et al.
Publicado: (2020)

Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma
por: Karakaya, Sinan, et al.
Publicado: (2023)

Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo — challenges and prospects
por: Jakoby, Judith, et al.
Publicado: (2015)

Postoperative Management in Patients with Pheochromocytoma and Paraganglioma
por: Mamilla, Divya, et al.
Publicado: (2019)

Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin
por: Bornstein, Stefan, et al.
Publicado: (2022)

Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review
por: Li, Minghao, et al.
Publicado: (2021)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
por: Lang, Fengchao, et al.
Publicado: (2021)

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
por: ZITZMANN, KATHRIN, et al.
Publicado: (2013)

Correction to: Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review
por: Li, Minghao, et al.
Publicado: (2021)

Metabolome-guided genomics to identify mutations in isocitrate dehydrogenase, fumarate hydratase and succinate dehydrogenase genes in pheochromocytoma and paraganglioma
por: Richter, Susan, et al.
Publicado: (2018)

Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
por: Kuo, Mickey J. M., et al.
Publicado: (2022)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia
por: Yang, Chunzhang, et al.
Publicado: (2015)

The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
por: Peng, Song, et al.
Publicado: (2020)

Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2021)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

PSUN27 Largest Cohort of Cervical Spine Metastases of Pheochromocytoma/Paraganglioma in the Setting of SDHB Mutation
por: Pacak, Karel, et al.
Publicado: (2022)

Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors In Vitro: Antitumoral Effects
por: Jin, Xi-Feng, et al.
Publicado: (2020)

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
por: Jin, Xi-Feng, et al.
Publicado: (2021)

SAT305 Clinical Characteristics And Outcomes Of Patient With Metastatic Pheochromocytoma/Paraganglioma (PPGL) And Extreme Elevated Biochemistry
por: Prodanov, Tamara, et al.
Publicado: (2023)

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gme59vf2br0lgcdktquptfopif